578 related articles for article (PubMed ID: 32912710)
1. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
Wei XB; Wei W; Ding LL; Liu SY
Prim Care Diabetes; 2021 Apr; 15(2):208-211. PubMed ID: 32912710
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Duan XY; Liu SY; Yin DG
Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
Qiu M; Ding LL; Wei XB; Liu SY; Zhou HR
J Cardiovasc Pharmacol; 2021 Jan; 77(1):34-37. PubMed ID: 33136765
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
Qiu M; Ding LL; Zhou HR
Am J Cardiovasc Drugs; 2022 Jan; 22(1):69-81. PubMed ID: 34231123
[TBL] [Abstract][Full Text] [Related]
5. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
6. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
Cao H; Liu T; Wang L; Ji Q
Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
11. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
Giugliano D; Scappaticcio L; Longo M; Caruso P; Maiorino MI; Bellastella G; Ceriello A; Chiodini P; Esposito K
Cardiovasc Diabetol; 2021 Sep; 20(1):189. PubMed ID: 34526024
[TBL] [Abstract][Full Text] [Related]
12. GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.
Pablo A; Evelyn B; Claudia F; Yanina MA
Curr Hypertens Rev; 2021; 17(2):149-158. PubMed ID: 33238857
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
[TBL] [Abstract][Full Text] [Related]
15. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
Qiu M; Ding L; Zhou H
Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
Giugliano D; Maiorino MI; Bellastella G; Longo M; Chiodini P; Esposito K
Diabetes Obes Metab; 2019 Nov; 21(11):2576-2580. PubMed ID: 31373167
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
19. Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes.
Papazafiropoulou AK; Melidonis A; Antonopoulos S
Curr Pharm Des; 2021; 27(8):1035-1042. PubMed ID: 32912116
[TBL] [Abstract][Full Text] [Related]
20. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Chang R; Liu SY; Zhao LM
Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
